NZ606538A - Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
- Google Patents
Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim IntfiledCriticalBoehringer Ingelheim Int
Publication of NZ606538ApublicationCriticalpatent/NZ606538A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present disclosure relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy. In one embodiment the DPP-4 inhibitor is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine and is used in combination with metformin. In a sub-embodiment the type 2 diabetes patient with inadequate glycemic control despite metformin therapy has HbA1c at baseline ≥ 9 %.
NZ606538A2009-01-072010-01-07Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
NZ606538A
(en)
Hydrochlorides of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their use as medicaments and pharmaceutical composition
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.